IFNG and neoplasm: In NMIBC, T1 tumours (combined from Northwestern Memorial Hospital (NMH) [12] and UROMOL2021 [14]) were split by the IFNγ-signature into high and low groups (Figure 2A), with tumour recurrence being 50% more likely in patients in the IFNγ-signaturelow group (Figure 2B).